CMDBioscienceSM Inc.

CMDBioscienceSM Inc. specializes in the synthesis of DNA and RNA oligonucleotides, providing customized solutions for molecular biology research, diagnostics, and therapeutic development. CMDBioscienceSM Inc. is engaged in the synthesis of DNA and RNA oligonucleotides.

The company is headquartered in New Haven, US. On December 24, 2012, CMDBioscienceSM Inc. successfully raised USD 1. 0 mn in a Series A funding round from investors including Enhanced Capital Partners, Launch Capital, and Connecticut Innovations.

The company has undergone no significant changes in business operations since its inception. CMD Biosciences specializes in the synthesis of DNA and RNA oligonucleotides, offering a comprehensive range of over 100 modifications tailored to meet diverse research needs. Their core product line includes guaranteed oligos that are deprotected, desalted, and PAGE controlled, ensuring high purity and reliability for laboratory applications. Customers can order oligos with various labels, including fluorescent and non-fluorescent options, and other chemical modifications suited for hybridization probes, making their products essential for molecular biology research, diagnostics, and therapeutic development.

The company primarily serves academic institutions, biotechnology firms, and pharmaceutical companies across North America, Europe, and Asia, facilitating a wide array of applications in genetic research and development. CMD Biosciences operates on a transactional model where customers place orders for oligos through their web-based platform. Typical transactions involve the purchase of custom oligonucleotides in various quantities, ranging from Mass Oligos to Bulk Oligos, allowing clients to select specific modifications and labeling options. Pricing structures are designed to accommodate both small-scale and large-scale orders, with expedited shipping options available for time-sensitive research needs.

The company’s flagship offerings, such as their Mass Oligos™, are particularly favored for their quick delivery turnaround, reinforcing their position in the competitive life sciences market. Overall, CMD Biosciences maintains a diverse revenue stream by catering to a broad spectrum of scientific clients, ensuring a steady demand for their specialized products and services. Following its recent Series A financing round on December 24, 2012, where CMDBioscienceSM Inc. raised USD 1.

0 mn, the company plans to leverage these funds to enhance its product offerings and expand its market reach. Upcoming projects include the launch of new oligonucleotide modifications aimed at expanding their product line. The company aims to enter new geographic markets in Europe and Asia by 2024, targeting academic and pharmaceutical sectors that require advanced molecular biology tools. The funding will facilitate product development and marketing efforts essential for these strategic expansions.